Subscribe to Newsletter
Diagnostics Point of care testing, Analytical science

C. difficile, But Not Impossible

Clostridium difficile is notorious among hospital patients and staff for its ability to infect the bowel and cause (sometimes deadly) diarrhea. Because of its high toxigenicity and increasing antibiotic resistance, early diagnosis of C. difficile infection (CDI) is vital to stopping the spread of this disease and ensuring effective treatment. But current testing methods have a number of limitations; they cannot accurately determine infection severity, offer low sensitivity, and do not allow for quantification.

By combining the benefits of a lateral flow assay (LFA) with surface-enhanced Raman scattering (SERS), researchers from the University of Strathclyde and Newcastle University, UK, have overcome these limitations and offered hospital laboratories an ultra-sensitive, fast, cheap, and user-friendly test for CDI (1).

Their SERS-based LFA platform enables sensitive quantification (down to 0.01 pg/μL) of two key biomarkers, SlpA and ToxB, in 20 minutes. Importantly, this is the first time a duplex test for both biomarkers has been studied – and it could offer more accurate CDI diagnosis (and pathogenicity determination) without cross-reactivity from similar species. “Also, the use of the handheld Raman spectrometer means this measurement can be done at point-of-care and is highly portable, making it suitable for use in a wide range of situations,” says Duncan Graham, Head of the Department of Pure and Applied Chemistry at the University of Strathclyde.

The Newcastle team had previously worked on a C. difficile assay with lateral flow, but the method (which relies on a visual assessment with the naked eye) wasn’t sensitive enough for use in a clinical setting. “When we started collaborating with Neil Keegan from the Translational and Clinical Research Institute at the University of Newcastle, we recognized that the lateral flow assay could be merged with SERS detection to give the sensitivity required,” says Graham. 

The team’s next step is to move onto clinical samples. “So far we’ve used simulated clinical samples (synthetic feces), but it’s time for the real stuff now,” adds Graham.

This article was first published here in The Analytical Scientist

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. WA Hassanain et al., Analyst, 146, 4495 (2021). PMID: 34184680.
About the Author
Lauren Robertson

By the time I finished my degree in Microbiology I had come to one conclusion – I did not want to work in a lab. Instead, I decided to move to the south of Spain to teach English. After two brilliant years, I realized that I missed science, and what I really enjoyed was communicating scientific ideas – whether that be to four-year-olds or mature professionals. On returning to England I landed a role in science writing and found it combined my passions perfectly. Now at Texere, I get to hone these skills every day by writing about the latest research in an exciting, creative way.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine